HOME >> MEDICINE >> NEWS
Drug-eluting stents adopted quickly, with early disparities

DURHAM, N.C. -- In the first comprehensive survey of its kind, Duke Clinical Research Institute researchers have documented that while the adoption of new drug-eluting stents has been rapid, their use has not been universally uniform among patients receiving them.

Furthermore, the researchers said, about one-third of the new stents were placed in patients with clinical characteristics for which such stent use has not yet been approved by the Food and Drug Administration (FDA). However, the researchers said that their finding of a high rate of "off-label" usage should be seen more as an impetus for further clinical trials rather than an immediate safety issue, since cardiologists have been placing traditional stents for more than 10 years and are comfortable with the procedure.

Stents are tiny mesh tubes that are inserted into the site of a blockage in a coronary artery that has been opened during balloon angioplasty. However, a principal complication of the procedure has been the high rate of treated arteries becoming blocked again, a process known as restenosis.

In an attempt to improve stents to keep treated arteries open, stent manufacturers coated them with a chemotherapeutic agent that limits the formation of scar tissue inside the artery. So far, clinical trials have shown that these new stents can reduce the restenosis rate to single digits from the 20 to 30 percent rate of the older stents. The first drug-eluting stent received FDA approval in April, 2003.

"Drug-eluting stents are truly breakthrough products in treating coronary artery disease, and in our analysis of the early trends of the their use, we found disparities in terms of age, race and socio-economic factors," said Duke cardiologist Sunil Rao, M.D., who presented the results of the Duke analysis Nov. 10, 2004, at the American Heart Association's annual scientific sessions in New Orleans.

"We also found that the rate of increased usage for off-label use was
'"/>

Contact: Richard Merritt
Merri006@mc.duke.edu
919-684-4148
Duke University Medical Center
10-Nov-2004


Page: 1 2 3

Related medicine news :

1. Study finds drug eluting stents as effective as vascular brachytherapy in preventing restenosis
2. Study says rare allergic reactions to drug-eluting stents may raise risk for heart attack
3. Coronary stents do not improve long-term survival
4. Early reports of thrombosis after insertion of drug-eluting stents
5. Drug-coated stents effective in real world patients
6. Study highlights efficacy of sirolimus stents to prevent restenosis for PTS with CAD
7. Stanford computer model shows bypass surgery more cost-effective than stents
8. Research explores why some internationally adopted children excel while others struggle
9. Mandel School researchers receive $700,000 for study to promote well-being of adopted children
10. Sandia-developed foam likely would stop SARS virus quickly, Sandia/Kansas State team shows
11. New marker for early diagnosis of kidney failure identified

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/23/2017)... ... August 23, 2017 , ... ... of hospitals nationally that earned the designation of High Performing Hospitals by U.S. ... high performing indicates a hospital was significantly better than the national average in ...
(Date:8/23/2017)... (PRWEB) , ... August 23, 2017 , ... ... team to support long-term strategic growth plans, announcing the hiring of Kevin Keelan ... certified technology consultant and seasoned sales manager, Keelan will be working with Virsys12 ...
(Date:8/22/2017)... , ... August 22, 2017 , ... ... collection of unique masks and serums that perfectly fuse the beauty of naturally ... at the 2017 Indie Beauty Expo on August 23rd & 24th in New ...
(Date:8/22/2017)... ... August 22, 2017 , ... Pivot ... addition of Zack Tisch as the firm’s new Consulting Services Executive. Mr. Tisch ... firm’s national accounts, from assisting clients with initial vendor selection and pre-implementation planning ...
(Date:8/22/2017)... ... ... Five Star Glass is new to the Texas market, but is proudly managed by widely ... makes and models, in Grand Prairie, TX, located in the center of the DFW Metroplex, ... owned business for the past 40 years with 32 convenient locations in Texas, Nevada and ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)... Fenita J. Caldwell is ... Lifetime Professional in the Field of Healthcare. Caldwell ... Pharmaceuticals, AG. Her skills and areas of expertise ... Fenita ... experience as a highly successful sales specialist in ...
(Date:8/2/2017)... , Aug. 2, 2017  Life Flight Network and ... The agreement improves patient care and operational efficiency for patients ... Springfield , Cottage Grove , and ... medical transportation. PeaceHealth and Life Flight Network work collaboratively to ... during transport, or when a time sensitive emergency exists. ...
(Date:8/1/2017)...   CerSci Therapeutics , a non-opioid drug development ... has received notice from the National Institute on Drug ... that it has been awarded a Direct-to-Phase II Small ... 2017 with an additional $1,000,000 to follow in 2018. ... of their lead non-opioid drug candidate CT-044 to the ...
Breaking Medicine Technology:
Cached News: